Download this application note to learn how a comprehensive database curated by experts can support clinical decision making in rare cancers, courtesy of QIAGEN.
New sequencing approaches, such as next-generation sequencing (NGS), have more clinical utility compared to conventional genetic testing tools, particularly for rare cancers.
The increased sensitivity of such approaches leads to a lot of data on genetic variants, requiring a database where each variant
Powerful software like QCI Interpret One does all of that to help understand the prognosis, diagnosis, and therapeutic options available for individuals with rare cancers.
Today's Clinical Lab needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at anytime.
For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our privacy policy by clicking here.
Today's Clinical Lab c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, USA, 19801
Toll-Free: 888-781-0328 | (705) 528-6888
Email: privacy@clinicallabmanager.com
© 2021 TODAY'S CLINICAL LAB. ALL RIGHTS RESERVED.